On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer In­gel­heim’s BD team is on a glob­al deal spree. The Ger­man phar­ma com­pa­ny just wrapped its third deal in 3 weeks, go­ing back to Ko­rea for its lat­est pipeline pact — this time fo­cused on id­io­path­ic pul­monary fi­bro­sis.

They’re hand­ing over $50 mil­lion to get their hands on BBT-877, an ATX in­hibitor from Ko­rea’s Bridge Bio­ther­a­peu­tics that was on dis­play at a sci­ence con­fer­ence in Dal­las re­cent­ly. There’s not a whole lot of da­ta to eval­u­ate the prospects here.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER